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Abstract
Background: Genetic contributions to major depressive disorder (MDD) are thought
to result from multiple genes interacting with each other. Different procedures have
been proposed to detect such interactions. Which approach is best for explaining
the risk of developing disease is unclear.
This study sought to elucidate the genetic interaction landscape in candidate genes
for MDD by conducting a SNP-SNP interaction analysis using an exhaustive search
through 3,704 SNP-markers in 1,732 cases and 1,783 controls provided from the
GAIN MDD study. We used three different methods to detect interactions, two
logistic regressions models (multiplicative and additive) and one data mining and
machine learning (MDR) approach.
Results: Although none of the interaction survived correction for multiple
comparisons, the results provide important information for future genetic interaction
studies in complex disorders. Among the 0.5% most significant observations, none
had been reported previously for risk to MDD. Within this group of interactions, less
than 0.03% would have been detectable based on main effect approach or an a
priori algorithm. We evaluated correlations among the three different models and
conclude that all three algorithms detected the same interactions to a low degree.
Although the top interactions had a surprisingly large effect size for MDD (e.g.
additive dominant model Puncorrected = 9.10E-9 with attributable proportion (AP)
value = 0.58 and multiplicative recessive model with Puncorrected = 6.95E-5 with odds
ratio (OR estimated from β3) value = 4.99) the area under the curve (AUC) estimates
were low (< 0.54). Moreover, the population attributable fraction (PAF) estimates
were also low (< 0.15).
Conclusions: We conclude that the top interactions on their own did not explain
much of the genetic variance of MDD. The different statistical interaction methods
we used in the present study did not identify the same pairs of interacting markers.
Genetic interaction studies may uncover previously unsuspected effects that could
provide novel insights into MDD risk, but much larger sample sizes are needed
before this strategy can be powerfully applied.
Keywords: Additive interaction, Multiplicative interaction, Logistic regression,
Data mining and machine learning, Major depressive disorder
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Introduction
Major depressive disorder (MDD) is a common [1] complex [2] psychiatric disorder
with major health concerns worldwide [3,4]. Heritability estimates of ~37% [5]
implicate a partially genetic causation. This has motivated numerous linkage studies
[6], association studies of candidate genes [7] and recently even a few genome-wide
association studies (GWAS) [8]. However, convincing replication across independent
studies is lacking, and no major MDD risk locus has been identified leaving much of
the estimated heritability unexplained. This implies that MDD is genetically far more
complex than previously expected, with influences from both allelic and locus heterogene-
ities in parallel with exposures to adverse social events and behavior, hampering success
in identifying genetic risk factors [6,7,9] within this heterogeneous syndrome.
A recent mega-analysis shows that it is unlikely that MDD is caused by a few genetic
risk factors with large effect [8]. The explained genetic variance is still low which opens
up for the possibility that interaction effects from both genetic and environmental risk
factors are important source for explaining the remaining heritability [10-14]. The role
of interactions (also known as epistasis or synergy) as a versatile mechanism for
regulating health and disease has been proposed [15-18], and has recently been suggested
to increase risk for schizophrenia [19,20] and bipolar disorder [21]. Increasing the sample
size alone and using a single gene model will not reveal the complete genetic architecture
of MDD. Detailed characterization of the interacting landscape will thus be a critical
factor in understanding why people are at risk for this debilitating disorder [22,23].
Numerous methods are available for detecting gene-gene interactions [24-26], each of
which has been designed with different assumptions of how biological interactions can
be detected with statistical methods.
Historically, two statistical principles have evolved: one represents genetic model-based
methods and one model-free method [27,28]. The model-based approaches are designed
to calculate interactions based on linear regression [29]. The model-free systems use
different applications of data mining and machine learning approaches [30,31]. It is not
yet clear which model is best at identifying interacting factors involved in disease
susceptibility.
For this study we stated two hypotheses. Our first hypothesis was that common
genetic risk factors in a set of candidate genes, act through a variety of interactions in
the susceptibility for MDD. Our second hypothesis was that no single available statistical
method would completely capture all possible forms of interactions. We therefore chose
three different methods for modeling potential genetic interactions and examined to what
extent these different statistical methods report synergy effects with relevance for
susceptibility to MDD.
To address these questions we designed an incremental approach (analytic strategy in
Additional file 1: Figure S1) with a reduction of genetic heterogeneity using two
cohorts, to systematically examine SNP-interaction effects using both genetic
model-based and model-free methods. The former consists of one additive and one
multiplicative interaction method. The model-free method was a multifactor dimensionality
reduction (MDR) approach.
The objective was not to compare the statistical methods for detecting interaction
but we evaluated the methods in those situations where the combinations of pairs of
tested SNPs were identical. Both study populations we used in this study have been
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used for genome-wide association analyses of MDD [32,33]. The candidate genes we
used in this study have not been tested in a separate analysis previously.
Methods and materials
Study populations
The Sequenced Treatment Alternatives to Relive Depression (STAR*D) study [34] and
the Genetic Association Information Network, GAIN major depressive disorder study
[35] provided the two study populations. STAR*D subjects were outpatients from primary
care or psychiatric clinics who met DSM-IV criteria for single or recurrent non-psychotic
MDD, age 18–65 years, with no history of bipolar disorder, schizophrenia, schizoaffective
disorder, or any other psychotic disorder. The STAR*D sample comprised of 634 controls
matched with 1,256 cases. GAIN cases were recruited from four different longitudinal
studies of patients with MDD in the Netherlands [32,36-38]. Inclusion criteria were life-
time diagnosis of MDD (DSM-IV), and an age between 18–65 years. A sample of 1,822
biologically unrelated controls was matched with 1,821 cases. Full details of both study
populations are available in Additional file 2: Supplementary Materials.
Candidate gene selection SNP genotyping and quality control
The 68 candidate genes we used in this study were derived from in the STAR*D study
and were prioritized on the basis of previous results of association to MDD, for
association to response to antidepressant treatment [39] (Additional file 3: Table S1).
Full details of genotyping, marker selection and QC analyses are provided in Additional
file 2: Supplementary Materials.
We included markers that mapped within 10 kb of each candidate gene according to
NCBI36/hg18. After QC analysis the STAR*D dataset consisted of 1,240 cases and 630
control and 654 SNP markers. The GAIN dataset consisted of 1,732 cases, 1,783
controls and 1,516 SNPs.
Statistical power
Power calculations are conditional on estimates of the correct specifications of the
underlying genetic model. Since such a ‘true’ model is not known, we allowed several
model parameters to vary, including misspecification of the diagnosis. The mean power
estimates for the single marker analyses were 53% in GAIN and 32% in STAR*D samples
(Additional file 4: Table S2). Detailed power calculations are provided in Additional file 2:
Supplementary Materials.
As a method for power calculation in the additive interaction method or the
MDR approach is not validated we have not generated any estimates of power in
the interaction analyses.
Marker selection for SNP-SNP interaction analysis
For the logistic regression methods where it became unmanageable to test interactions
between all markers, our approach was to prioritize markers according to predicted
attributable dependencies [28] defined through main effect (P < 0.05, n = 43) in single
marker analysis [40] and from markers with no-main effects (n = 49) using predicted
dependencies based on a computational filtering approach implemented in the MDR
software [41]. In total, for the two logistic regression methods, 92 markers were tested
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against the full dataset of 3,704 markers. For the genetic model-free MDR approach,
we managed to include the full SNP-dataset using an exhaustive interaction method.
We did not filter the markers for pair-wise linkage disequilibrium (LD) patterns.
However, when presenting the top 10 interactions for each model LD pruning was
performed with an r2 value > 0.2. Interaction analyses were only performed for
autosomal markers because the current software versions do not handle chromosome
X markers correctly.
Statistical analyses
Single marker association analysis and meta-analysis
For autosomal markers association was tested using a Cochrane Armitage test (SNPtest)
assuming an additive model, using the top 4 principal components as covariates. For
chromosome X markers the Unphased software (additive allele-wise model for the log odds
ratio) was used. Fixed effects (Mantel-Haenzel) or random effects (DerSimonian-Laird)
meta-analyses were performed after Woolf ’s test for heterogeneity with an applied
threshold of P < 0.05, performed in R (rmeta-package). The single-marker analysis and
meta-analysis was performed in order to assess a shared genetic background to MDD
between the two study populations. We used nominal P value as our cutoff for defining
homogeneity in association between the two study populations. The threshold for reporting
association to MDD in the single marker analyses was estimated by a family-wise error rate
(FWER), using Bonferroni’s method.
SNP-SNP interaction analysis
We considered three different algorithms for detecting SNP-SNP interactions.
Interaction effects in the additive and multiplicative methods were tested using logistic
regression implemented in a JAVA coded software designed to handle large datasets
(coded in our own lab and available upon request) which is a modified version of the
GEIRA software [42]. Testing for interaction effects using a machine learning and data min-
ing approach was conducted in a MDR software [43]. See Additional file 2: Supplementary
Materials for detailed descriptions of these algorithms. To examine the ability of the
identified interactions to predict disease status, we calculated the sensitivity and speci-
ficity scores. The population attributable fraction (PAF) was calculated to quantify the
proportion of MDD affected individuals attributed to the genetic risk (described in
Additional file 2: Supplementary Materials).
Test for correlation between identified pair-wise set of markers between different statis-
tical interaction methods was estimated by calculating Pearson’s r (carried out in R).
Results
Assessment of genetic heterogeneity between STAR*D and GAIN
We considered a nominal threshold of association (P < 0.05) for evaluating a shared
genetic background in the 68 candidate genes to MDD between the two study
populations.
Of the 173 SNPs that were genotyped in both STAR*D and GAIN none were found
to be nominally associated in both study populations. Of the 34 SNPs found at P < 0.05
in STAR*D 10 markers were genotyped in GAIN.
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Of the 57 SNPs with P < 0.05 in GAIN 3 markers were genotyped in STAR*D
(Additional file 5: Figure S2A-B and Additional file 6: Table S3A-B). We imputed
markers in GAIN for the 15 genes that contained nominally associated markers in
STAR*D. This analysis generated 28 additional SNPs at P < 0.05 of which none
overlapped with nominally associated markers in STAR*D (Additional file 6: Table S3A
and C). None of the nominally associated markers in the two study populations were in
high LD (r2 ≥ 0.8).
As a final step to test for heterogeneity we included both study populations and
performed a meta-analysis. We selected the nominally associated SNPs in STAR*D that
were identical with any marker in GAIN, genotyped or imputed (n = 15). However,
only 10 markers had the same risk allele and only one marker was nominally associated
in the meta-analysis, rs2137330 in the NR3C2 gene, pooled OR = 1.13 and P = 0.039
(Additional file 5: Figure S2C).
A shared genetic risk between the two study-populations could not be confirmed.
Therefore only the GAIN sample, which was the sample with more complete genotyping
in the candidate genes, was used for the subsequent gene-gene interaction analyses.
Overall interaction findings
Genotypes from 3,704 imputed or genotyped markers in the 63 tested candidate genes
(chromosome X genes excluded and two autosomal genes without markers in GAIN)
were tested for interaction effects. None of the tests generated P values that survived
correction for multiple testing with permutation in either the logistic regression or MDR
methods. Additional file 7: Figure S3A-C illustrates the complete set of interactions
generated from the different methods that were used for the assessment of interaction
effects. For each one of the linear models, 340,768 interactions were evaluated (testing 92
against 3,704 markers), whereas for the MDR method 3,704 markers were tested in an
exhaustive interaction analysis.
The large number of tests performed penalized our approach with regard to report a
significant interaction, and none of the tests generated a P value that survived correction
for multiple testing.
In spite of the non-significant results there are interesting observations worth noting.
Among the model-based methods, a large number of interactions were observed with P
values of interaction below a nominal significance level (Additional file 7: Figure S3A-B).
We therefore hypothesized, based on the notion that our study sample was markedly
underpowered, that the 0.5% most significant interactions would be enriched for interac-
tions involved in MDD-susceptibility. In a very conservative approach, we therefore next
considered the top 10 ranked interactions (LD filtered, r2 ≤ 0.2) in each one of the
different interaction methods as a source of information for better understanding of the
genetic interacting landscape in these candidate genes for MDD-susceptibility.
Our next observation concerns the unrealistically large fraction of negative AP
estimates. In some instances the observed AP values exceeded the theoretical limit of −1.0
(i.e. AP < −1.0). This observation prompted us to address the question if the negative AP
values are valid estimates for the reduction of risk (Additional file 8: Figure S4A-D). We
observed a skewing of AP values towards the negative side of the distribution and a
correlation between large negative AP values and few individuals in one of the exposure
groups. There did not appear to be a correlation between the lowest observed OR and
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negative AP, as AP < −1.0 was observed for both OR close to 1.0 and large OR’s. However
there was a negative correlation between the largest observed single exposure OR and AP
when AP < 0. We concluded that although these negative AP values may indicate negative
interactions, their magnitudes are far too large to warrant statistical analysis. No
deflecting pattern was observed among positive AP values.
Top 10 interactions
Of the ten strongest interactions generated from the three different algorithms, none
represents pairs of markers that have previous been reported to interact in the susceptibility
to MDD. We also noted that within this group of interactions the markers did not represent
those selected based on predictive interaction effects using main effect or an algorithm that
predict involvements SNP-SNP interactions. Although the three different methods
generated metrics of interaction effects with different assumptions and were thus not
readily comparable, we further noted that the estimates of interaction effects were
surprisingly strong for the regression models.
Among the ten most significant interactions in the dominant additive model, the
effect measures of interaction (AP) were relatively strong (AP > 0.51, uncorrected
P < 3.77E-5). The most significant interaction (uncorrected P = 9.10E-9, permuted
P = 0.14) consisted of two markers located in the ARGHAP10 gene, rs9332471 and
rs6845865 (AP = 0.58) (Table 1A). The rs9332471 marker also shows interaction
with another marker, rs2306910, in the ARHGAP10 gene. These 3 markers are in
a weak LD (r2 ≤ 0.2) with each other. This gene is involved in intracellular signaling and
has a role in regulation of apoptosis. In the recessive model (Table 1B), the strongest sig-
nal was observed between markers located in the GRIN2B and RNF20 genes (AP = 0.69,
uncorrected P = 7.65E-7, permuted P = 0.56).
For the additive model the strongest interaction effect, AP value of 0.72 (95% C.I.,
0.42-1.02), was for markers in the genes ARHGAP10 and GRIK4.
In the multiplicative interaction method (Table 1C-D) the strongest effect measure,
for the interaction term β3, in the recessive model (ORrec = 4.99, uncorrected P = 6.95E-5)
was for markers in GRIN2A and GRIN2B genes and for the dominant model (ORdom = 4.16,
uncorrected P = 4.41E-5) for markers in GRIK1 and GRIK4 genes. Additionally,
there was a marked interaction (ORrec = 3.70) from the ARHGAP10 gene in combin-
ation with the SLC6A2 gene, and from the HTR2A gene in combination with the COMT
gene (ORdom = 3.05).
Using the model-free approach, there were no interaction events with large effect,
OR < 1.51 (Table 1E). The accuracy for how classification could be predicted into high-
versus low risk groups was relatively modest (top value = 0.55, permuted P = 0.14).
The marginal difference in ratio of affected to unaffected individuals in high versus low
risk groups explains the weak cross-validation metric (CVC) value of 4/10, confirming
that the study population was obviously too small to identify shared genetic interacting
loci with small effects with the MDR approach. Full details of result metrics of the top
10 interactions are provided Additional file 9: Table S4.
Test for correlation between the different interaction methods
To find out to what extent the different algorithms identified pairs of markers of
relevance to disease we performed a test for correlation between the three interactions
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Table 1 Result of the 10 most nominally significant interactions
A: Additive dominant
Marker 1 Marker 2 Interaction statistics
Cases/Controls with marker 1 and marker
2 conferring risk (1) or no-risk (0)
Permuted
Chr Gene Rs Chr Gene Rs AP (95% C.I.) AP P P PAF AUC 00 01 10 11
4 ARHGAP10 rs9332471 4 ARHGAP10 rs6845865 0.58 (0.39:0.78) 9.10E-9 0.14 0.147 0.5153 1009/1073 169/174 475/500 78/33
6 HTR1E rs6922679 16 GRIN2A rs17570500 *0.71 (0.42:1.002) 1.92E-6 0.57 0.142 0.5046 48/50 20/6 1332/1388 310/321
4 ARHGAP10 rs9332471 4 ARHGAP10 rs2306910 0.63 (0.37:0.89) 2.40E-6 0.61 0.149 0.5136 1201/1273 190/182 233/238 35/12
4 ARHGAP10 rs9991394 4 ARHGAP10 rs12645249 0.59 (0.34:0.84) 2.58E-6 0.63 0.146 0.5173 1162/1257 332/326 154/158 47/18
9 GRIN3A rs7873495 11 GRIK4 rs10892635 **-1.08 (-1.56:-0.59) 1.26E-5 0.90 0.139 0.5216 290/258 10/30 1308/1390 122/105
12 GRIN2B rs12371702 9 GRIN3A rs13292935 ***-0.92 (-1.35:-0.50) 1.89E-5 0.95 0.146 0.5375 1003/1122 442/377 236/202 51/82
12 GRIN2B rs11832404 4 NR3C2 rs982076 **-1.23 (-1.81:-0.65) 3.49E-5 0.99 0.142 0.5266 257/182 10/24 1268/1367 92/86
12 GRIN2B rs11832404 11 GRIK4 rs7928347 **-1.27 (-1.89:-0.66) 5.24E-5 0.99 0.142 0.5300 255/185 7/18 1234/1332 87/78
4 ARHGAP10 rs9332471 9 SLC1A1 rs184204 0.53 (0.27:0.79) 6.28E-5 0.99 0.145 0.5157 1212/1292 194/183 271/282 53/23
5 GRIA1 rs17114975 12 GRIN2B rs1012587 *0.64 (0.33:0.95) 6.54E-5 0.99 0.129 0.5084 83/79 24/8 1381/1448 241/245
B: Additive recessive
Marker 1 Marker 2 Interaction statistics
Cases/Controls with marker 1 and marker
2 conferring risk (1) or no-risk (0)
Permuted
Chr Gene Rs Chr Gene Rs AP (95% C.I.) AP P P PAF AUC 00 01 10 11
9 RNF20 rs16920473 12 GRIN2B rs2216127 0.69 (0.42:0.97) 7.65E-7 0.56 0.149 0.5238 377/446 1296/1305 12/14 46/14
4 ARHGAP10 rs4835456 11 GRIK4 rs4936540 0.72 (0.42:1.02) 2.70E-6 0.72 0.148 0.5136 1105/1176 22/23 582/571 22/6
4 ARHGAP10 rs6824449 16 SLC6A2 rs192303 ***-1.28 (-1.85:-0.72) 8.30E-6 0.86 0.149 0.5319 1293/1414 208/159 184/144 16/32


















Table 1 Result of the 10 most nominally significant interactions (Continued)
12 GRIN2B rs3764030 5 HTR4 rs6865654 0.68 (0.37:0.99) 1.27E-5 0.91 0.148 0.5063 1363/1423 47/48 231/235 22/7
11 GRIK4 rs7939968 4 NR3C2 rs12641471 0.52 (0.28:0.76) 2.03E-5 0.94 0.144 0.5170 1088/1165 192/186 275/292 69/32
4 ARHGAP10 rs6824449 16 GRIN2A rs11640235 ***-1.01 (-1.56:-0.55) 3.60E-5 0.98 0.149 0.5204 1355/1435 210/163 105/108 8/25
11 GRIK4 rs7939968 4 NR3C2 rs4835508 0.51 (0.27:0.75) 3.77E-5 0.98 0.143 0.5186 1029/1118 185/179 275/295 70/33
11 GRIK4 rs7939968 4 ARHGAP10 rs12641157 0.64 (0.33:0.94) 5.05E-5 0.99 0.148 0.5178 1347/1444 260/229 93/95 26/8
3 HTR3C rs6766410 6 LAMA4 rs6913656 ***-0.84 (-1.25:-0.43) 5.48E-5 0.99 0.148 0.5216 1210/1279 243/207 217/218 21/49
C: Multiplicative dominant
Marker 1 Marker 2 Interaction statistics
Cases/Controls with marker 1 and marker
2 conferring risk (1) or no-risk (0)
Permuted
Chr Gene Rs Chr Gene Rs OR (95% C.I.) P P PAF AUC 00 01 10 11
4 GRIA2 rs17244157 16 GRIN2A rs1861192 0.44 (0.30:0.64) 2.39E-5 0.85 0.120 0.5442 712/838 175/120 589/539 98/120
9 SLC1A1 rs10974611 6 LAMA4 rs2032568 0.47 (0.38:0.67) 3.60E-5 0.92 0.125 0.5389 536/624 154/116 699/682 145/195
12 GRIN2B rs12371702 9 GRIN3A rs13292935 0.41 (0.26:0.62) 3.72E-5 0.95 0.114 0.5375 1003/1122 442/377 236/202 51/82
4 GRIA2 rs17244157 16 GRIN2A rs16966731 0.45 (0.31:0.66) 3.78E-5 0.95 0.127 0.5322 572/642 147/88 798/808 135/162
21 GRIK1 rs379182 11 GRIK4 rs17124632 0.24 (0.12:0.48) 4.41E-5 0.97 0.148 0.5244 80/111 46/14 1165/1221 357/342
10 RPP30 rs11186343 7 HTR5A rs2919435 2.49 (1.60:3.89) 5.51E-5 0.98 0.130 0.5295 145/97 58/89 951/1028 558/555
3 NR1I2 rs6438549 12 GRIN2B rs12823982 0.45 (0.30:0.67) 7.17E-5 0.99 0.114 0.5333 927/1011 222/182 505/473 67/105
13 HTR2A rs666693 22 COMT rs8185002 3.05 (1.75:5.31) 8.82E-5 0.99 0.148 0.5325 596/548 34/61 927/1011 83/58
4 NR3C2 rs7691663 5 GRIA1 rs1422897 2.09 (1.44:3.02) 1.02E-4 0.99 0.110 0.5310 124/85 445/490 185/237 977/964


















Table 1 Result of the 10 most nominally significant interactions (Continued)
D: Multiplicative recessive
Marker 1 Marker 2 Interaction statistics
Cases/Controls with marker 1 and marker
2 conferring risk (1) or no-risk (0)
Permuted
Chr Gene Rs Chr Gene Rs OR (95% C.I.) P P PAF AUC 00 01 10 11
5 GRIA1 rs574071 11 HTR3B rs1672717 0.52 (0.39:0.71) 2.72E-5 0.70 0.132 0.5433 371/473 701/646 222/182 305/346
4 NR3C2 rs7691663 5 GRIA1 rs9686702 1.84 (1.38:2.44) 3.28E-5 0.76 0.117 0.5375 270/211 313/374 445/516 703/679
3 GSK3B rs1719889 16 GRIN2A rs1102967 0.55 (0.41:0.73) 3.30E-5 0.76 0.139 0.5423 228/345 569/517 308/289 534/552
11 GRIA4 rs17104807 22 COMT rs2020917 2.39 (1.57:3.63) 4.56E-5 0.86 0.118 0.5386 98/86 643/719 86/149 848/784
12 GRIN2B rs3764030 16 GRIN2A rs1868289 4.99 (2.26:11.03) 6.95E-5 0.96 0.133 0.5169 41/13 29/44 695/742 948/970
5 GRIA1 rs574071 16 GRIN2A rs1070548 2.21 (1.48:3.31) 1.17E-4 0.99 0.142 0.5284 517/532 819/860 70/110 186/135
9 NTRK2 rs1624327 16 GRIN2A rs1097784 1.94 (1.38:2.72) 1.19E-4 0.99 0.138 0.5332 562/581 639/662 128/186 237/178
4 ARHGAP10 rs6824449 16 SLC6A2 rs192303 0.27 (0.14:0.54) 1.68E-4 1.0 0.119 0.5319 1293/1414 208/159 184/144 16/32
6 GRIK2 rs7770500 6 LAMA4 rs2072019 2.06 (1.41:3.00) 1.76E-4 1.0 0.116 0.5133 139/102 666/719 119/164 792/781


















Table 1 Result of the 10 most nominally significant interactions (Continued)
E: MDR
Marker 1 Marker 2 Interaction statistics
Cases/Controls with genotype combination
at predicted risk group
Chr Gene Rs Chr Gene Rs Balanced accuracy PAF OR (95% C.I.) P High risk Low risk TPR FPR
12 GRIN2B rs1012587 3 HTR3C rs6762938 0.5513 0.0980 1.51 (1.32:1.73) 1.168E-09 907/751 825/1032 0.524 0.421
16 GRIN2A rs8045893 3 HTR3C rs6762938 0.5498 0.0900 1.49 (1.30:1.71) 4.452E-09 1033/887 699/896 0.596 0.497
6 HTR1E rs17222848 5 GRIA1 rs17515709 0.5480 0.0950 1.47 (1.28:1.68) 1.707E-08 933/790 799/993 0.539 0.443
11 GRIA4 rs609665 6 GRIK2 rs2518171 0.5476 0.0917 1.46 (1.28:1.68) 2.051E-08 982/842 750/941 0.567 0.472
6 GRIK2 rs17828670 3 GSK3B rs6771023 0.5470 0.0894 1.46 (1.28:1.67) 2.757E-08 1021/884 711/899 0.589 0.554
13 HTR2A rs9526240 11 BDNF rs6265 0.5468 0.0912 1.45 (1.27:1.66) 3.643E-08 984/847 748/936 0.568 0.475
16 SLC6A2 rs1814270 6 FKBP5 rs9462104 0.5465 0.1020 1.46 (1.28:1.68) 3.031E-08 809/668 923/1115 0.467 0.375
13 HTR2A rs17288723 9 GRIN3A rs11788456 0.5454 0.0937 1.44 (1.26:1.64) 8.039E-08 936/802 796/981 0.540 0.500
12 GRIN2B rs10845847 12 GRIN2B rs12301788 0.5454 0.0809 1.48 (1.29:1.71) 2.458E-08 1180/1053 552/730 0.681 0.591
17 SLC6A4 rs2020939 6 GRIK2 rs2749074 0.5448 0.1012 1.44 (1.26:1.65) 8.982E-08 812/677 920/1106 0.469 0.380
Linear models are presented in A-D and results from MDR analysis in E. All top interactions of each method are LD filtered (r2 < 0.2).
Abbreviations:
AP, attributable proportion due to interaction; Permuted P, permuted P value corrected for multiple comparisons; 00, 01, 10 and 11 denotes risk (1) or no risk (0) genotype for marker 1 and marker 2; OR, odds ratio
estimates for the interaction term in the multiplicative method; P values of the multiplicative method are derived for the interaction term; AUC, area under the curve metrics derived from the ROC analysis (metrics of
diagnose classifier for a particular set of par-wise markers); For the MDR method OR’s are calculated using the number of cases/controls in high and low risk groups as defined in the MDR analysis; Balanced accuracy,
statistical metrics estimate how accurate individuals are classified into high versus low risk groups; The MDR P values are derived from test for significance of the OR estimates; TPR (true positive rate) and FPR (false
positive rate) is the sensitivity and specificity metrics to test the diagnose classifier for a particular set of pair-wise markers; PAF, population attributable fraction, proportion of disease burden in the population due to
exposure to genetic risk.
Notes: Asterisk (*) denotes that recoding of the preventive factors was made before measures of interaction in the additive scale were calculated. Recoding was done as follows:
*00 to 10, 01 to 11, 10 to 00 & 11 to 01.
**00 to 01, 01 to 11, 10 to 00 & 11 to 10.


















methods. We computed the Pearson’s correlation coefficient (r) to test the covariance
of interactions among the 0.5% region in one method against the entire dataset of
another method. This test was used for combinations of all methods (Additional file 10:
Figure S5A-L). Only weak correlations could be identified. The measures of correlation
between the model-based methods and between the multiplicative dominant and MDR
yielded r = 0.28 and r = 0.33 respectively. An even weaker correlation was found
between the additive and MDR methods.
Model fitting and population attributable fraction
For the 10 most significant interactions attributable fraction (PAF) scores, sensitivity
and specificity scores or AUC values were calculated (Table 1A-E). No pairs of markers
performed substantially better than any others. None of the reported top interactions
on their own explained the diagnosis of MDD to large extent, confirming that two
interacting genetic risk factors with major implications to MDD in the general population
were not identified in the present study. This observation further support that the
interacting genetic landscape is likely to be highly evolved and many interactions are
underlying a diagnosis of MDD.
Discussion
A key determinant to understand why people are at risk of complex disorders is the
genetic architecture, i.e. number of risk loci, allele frequencies and interaction mechanism
between genetic and non-genetic risk factors. In fact, the issue of missing heritability can
most likely to a large extent be explained by interactions between risk factors.
Genetic risk for MDD is considered to partially be manifested from multiple genes
which interact with each other [44]. We have performed an analysis looking at the
genetic interacting landscape in candidate genes for MDD testing three different methods,
each one designed to detect plausible statistical interaction effects. No significant
interaction was identified. Without excluding the possibility that no genetic interaction
with risk for MDD is present in these candidate genes, we speculate that our study sample
is not large enough to permit identification of interacting genetic risk factors with small
effect due to the high number of independent tests performed. We therefore hypothesize
that the most significant interactions are enriched for interactions implicated in MDD-
susceptibility from these candidate genes and thus provides indicative information for
genetic risk for MDD (Table 1A-D).
Using the multiplicative interaction method, large effect sizes from the interaction
term were reported from interactions in the glutamate system. Measured as the attribut-
able proportion due to interaction (AP), the additive method identified pairs of markers
with large effects. An important note is however that estimates of AP do not make any
inference for how many exposures are present in the identified sufficient cause. Nor do
they describe the number of sufficient causes that they are involved in. Hence, the AP
value should not be interpreted as the proportion of risk to MDD that is explained by this
interaction but the excess risk for MDD among individuals with both risk factors which
are due to their interaction.
In the analysis using the model-free approach, the interaction with the best classifier
value (balanced accuracy) was not repeatedly validated. The poor consistency of
identified interactions is mirrored by the modest OR estimates and indicates the
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presence of many genetic factors that interact, each with only marginal risk
contribution to MDD. Since we observed that the same markers were involved in
several different 2-way models (Table 1) we employed a 3-way analysis for an additional
subset of markers using the MDR approach. We found (Additional file 2: Supplementary
Materials) that the top interaction was not consistently validated (3/10) and, without
precluding the possibility that no synergy effects with relevance to MDD exist in these
candidate genes, conclude that the curse of higher order of dimensions attenuates the
power to predict an interaction in a sparse dataset.
From the results of the analysis of sensitivity and specificity scores, we conclude that
none of the top interactions are on their own sufficient to explain why people develop
MDD (Table 1A-E). Previous studies [45] indicate that the best disease classifiers are
not necessarily found for interactions with low P values. Due to computational reasons,
we have not searched our dataset for interactions with large classifier scores among less
significant interaction events. Our interpretation is that the disease classifier scoring,
along with the results from many separate interactions with small effect suggests that
there is an extensive network of combined risk factors that underlies risk to MDD from
these candidate genes. Detecting gene-gene interactions with relevance to risk of
disorder can be more complicated and hard to interpret than expected, as theoretically,
a certain gene could be protective in combination with one gene but risk conferring in
combination with another gene. Following the same discussion, it is therefore unknown
whether the expected effect size of interactions will be substantially larger than
previously found in the single marker analyzes or whether the effect size will only be
marginally larger. Despite the absence of significant interactions after correction for
multiple testing, we advocate that the present study still holds crucial information that
merits further attention. Firstly, the approach to include markers without LD filtering
and with a limited restriction for pruning markers for predicted interaction effect pro-
vided insight into the interacting landscape in these 63 candidate genes. None of the
top 10 interactions in any method and only a minimal proportion of the interactions in
the top 0.5% region contained markers predicted to have interaction effects. However,
in respect of the two logistic regression methods one of the pair-wise markers was in
fact selected based on these two criteria and the observation in this case refers to
interactions with both markers selected based on predicted effects. This is of significant
interest since neither of the two a priori approaches we employed to select markers
with predicted interactions effects seems to be optimal. This is a great challenge for
future study designs if significantly interacting markers should be identified.
Secondly, to our knowledge none of the present top interactions have previously been
reported to interact in risk for MDD. We performed a literature search on PubMed
and the Genetic Association Database (http://geneticassociationdb.nih.gov/) and found
relatively few gene-gene interaction analyses have been conducted for MDD. There are
reports of interaction between BDNF and NTRK2 and the 5-HTTLRP region in the
SLC6A4 gene [46,47]. In the present study, no interaction involving these three genes
(in total 98 markers including the BDNF Val66Met polymorphism) were among the
0.5% most significant interactions in any of the methods. Thirdly, for the model-based
approaches we had expected to find the largest effects in groups with few individuals.
However, our preliminary results indicate that the genetic risk, in these candidate
genes, is shared by many and confers risk with small effect.
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Given the limited number of genotypes in the STAR*D study that were available at
the time when this study was initiated, in comparison to marker coverage in GAIN,
greatly reduced the possibility to produce identical markers between the STAR*D and
the GAIN samples. This situation has implications for our interpretation of genetic
heterogeneity between the two study populations. We made the conclusion based on
the nominal P value from single marker analysis and cannot exclude the possibility that
our decision would have been different if a much larger study populations would have
been available. Nevertheless, the study sample was predetermined and given the
circumstances with low power we conclude that for the given marker coverage the two
samples were heterogeneous in the genetic risk to MDD. We stress that even though
we presumed that the two study populations are different in the genetic risk to MDD
based on the single-marker analysis we cannot exclude that the interaction effects
might be shared.
Considering the region harboring the top 0.5% interactions we observed correlation
between P values from interactions for the model-based methods, and between the
multiplicative dominant and MDR methods. These correlations were however weak (r
value close to zero, although significant). Additionally, only a proportion of the top
0.5% interactions were found among the top 0.5% interactions in another method
(Additional file 10: Figure S5A-L). We, therefore, conclude that the different methods
for testing interactions will not select the same pairs of markers as potential candidates
to explain the risk of MDD which is not surprising given the different assumption
behind the methods. These results are consistent with those from experimental genetic
interaction studies in model systems which show that interactions corresponds to
definitions of both additive and multiplicative models [48] which support our study
design to search for interaction using different definitions.
The observation of negative AP estimates below −1.0 in our dataset was unexpected
(Table 1A-B). AP is defined as the proportion of disease that is attributed due to inter-
action among those who are exposed to both risk factors [49,50]. It has been claimed
that AP values can vary between +1 and −1 [51]. AP > 0 means excess risk, or positive
interaction, and AP < 0 means negative interaction, or protection between the two risk
factors [51,52]. It is therefore surprising that we frequently observed values below −1.0
in our dataset. It has previously been shown that measures of additive interactions
calculated by substituting OR with RR in case–control studies may not be reliable
estimates when the incidence of the disease is high, as the case for MDD where it is
15%,with inflation of the AP estimates as a consequence [52]. This cannot however be
the only explanation for AP values below −1.0 as we have observed the same distribution
in a dataset (data not shown) where we tested interaction between susceptibility SNPs for
multiple sclerosis which has a prevalence less than ~0.2% [53]. By correlating AP values
to several other measures (Additional file 8: Figure S4A-D) we demonstrate that AP
values are apparently not normally distributed [50] and moreover that negative AP values
were unexpectedly inflated at a low number of individuals in any risk group, as well as at
large OR values for single exposures. Our conclusion is that AP can attain large negative
values per se. A closer look at the definition of AP reveals the reason; the denominator
equals the OR of the full model, which sometimes is small for pairs of SNPs that exhibit
negative interaction. Thus, our interpretation is that negative values have a meaning for
estimating protection although it is hard to interpret the magnitude of that protective
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effect. Following the line of arguments and discussion above we decided to report on the
complete dataset but only comment on interaction with positive or synergistic interactions,
i.e. positive AP values.
Limitations
This study has several limitations. Firstly, the GAIN sample was underpowered for
finding genetic interacting risk factors with small effect. To retain the best power of the
remaining sample we did not test for interactions using any sub-categorization of MDD
diagnosis or gender as this would have reduced power. This might reduce our chance
to find genetic interacting risk factors for these separate categories. Because the present
study was shown to have limited power for identifying genetic risk factors with small
effects we designed the interaction analysis without partitioning the GAIN sample into
a testing and replication datasets. Our study should thus only be considered as an
explorative study which needs further confirmation. Secondly, due to the lack of prior
evidence for superiority of any method to give priority to markers with a predicted
major role in interactions effects [25,54] we reduced our chances of reporting a significant
interaction through our massive screening approach.
Conclusions
Our main objective of finding interacting genetic risk loci for MDD-susceptibility was
not fruitful. Despite the absence of significant results we advocate that there are still
interesting results in the present study. Firstly, with restriction to the 63 candidate
genes our results further support the hypothesis that MDD has an ologogenetic background
with an exceptionally evolved network of genetic interactions contributing small amount to
the overall-risk of developing MDD. Secondly, our study design to test all markers without
giving priority to a sub-sample of markers based on predicted interactions gave vital
information. None of the most significant interactions contains markers based on
main effect from single marker analysis or based on prediction using an a priori
algorithm. Moreover, we also conclude that there is a little overlap in interacting
markers identified in the different algorithms used. This might argue that none of the
algorithms are adequate on their own. Thus, our results motivate that both model-
based and model-free methods should be applied if interacting markers for complex
traits shall be identified.
Identification of such interactions may help us to prioritize which biological processes
that should be studied further in order to better understand MDD pathogenesis.
Additional files
Additional file 1: Figure S1. Flow chart of analytic strategy and summary findings. A brief overview of our
incremental strategy for finding shared common genetic risk factors using an exploratory study population
(STAR*D) and a replication sample (GAIN) and finally to explore the genetic interacting landscape in MDD. Number
of SNPs, analysis method and the main findings are presented at each stage. All P values related to single marker
analysis in the figure are uncorrected for multiple comparisons.
Additional file 2: Supplementary Materials.
Additional file 3: Table S1. List of 68 candidate genes. Gene names, genomic size and functions were generated
using the UCSC and KEGG databases (www.genome.ucsc.edu/, www.genome.jp/kegg/). Genes are listed according
to proposed hypotheses for involvement in regulation of MDD-susceptibility. Numbers of genotyped SNPs that
have passed the quality control filtering for each gene are also presented. Markers maps within 10 kb of each
candidate gene according to the NCBI36/hg18.
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Additional file 4: Table S2. Power calculations. A: Input parameters for power calculation and resulting mean
power estimates in each separate study. Power estimates were calculated under the significance level of 0.05.
Asterisk (*) indicates the power estimates using Bonferroni’s corrected P value for significance in each study
population; 0.05/654 (STAR*D) and 0.05/2,896 (1,516 + 1,380) (GAIN). B: Output trend statistics under each separate
parameter value settings (corresponding to a significance level of P < 0.05).
Additional file 5: Figure S2. -Log10 P values plotted for the single markers tested in the STAR*D and GAIN
samples. The 68 candidate genes are arranged in a relative scale along chromosome 1–22 and chromosome X. We
performed a bioinformatic search and found no overlap between nominally associated markers in the STAR*D or
GAIN samples with literature findings in the NHGRI GWAS catalog for risk to MDD. Nor were marker replicated in
either the discovery or replication analysis in the mega-analysis of genome-wide association studies for major
depressive disorder (Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium Mol Psychiatry.
2013. doi:10.1038/mp.2012.21). However, two nominally associated markers in the GAIN sample were located in
two genes (GRIA1 and GRIK3) which were found to be reported for risk to schizophrenia in NHGRI GWAS catalog.
A: −Log10 of the P values are plotted for 654 genotyped markers in the STAR*D sample. The 10 nominally
associated markers that were identical with markers genotyped in the GAIN dataset and included in the meta-analysis
are highlighted in red. Threshold values for the nominal P value of 0.05 and Bonferroni’s corrected P value (7.6E-5) are
illustrated. B: −Log10 of the P values are plotted for 1,516 genotyped (black) and 1,380 imputed (blue) markers in the
GAIN sample. The 10 nominally associated markers that were identical with nominally associated markers in the STAR*D
dataset and included in the meta-analysis are highlighted in red. Threshold values for the nominal P value of 0.05 and
Bonferroni’s corrected P value (1.7E-5) are illustrated. C: −Log10 of the P values are plotted for the 10 markers tested in
the meta-analysis.
Additional file 6: Table S3. Nominally associated markers identified from single marker analysis in the STAR*D
and GAIN samples. A: Results of single marker association in STAR*D. B: Results of single marker association in
GAIN. C: Results of single marker association in GAIN (imputed markers).
Additional file 7: Figure S3. Results of SNP-SNP interaction analyses. -Log10 P or balanced accuracy values of the
interaction tests are plotted against the rank of the test in each method. Column charts depicts (i) number of
interactions at P < 0.05 (ii) number of interactions in top 0.5% region and (iii) the number of interactions with
predicted effects (main effects, P < 0.05, or using an a priori algorithm) in the total dataset. Number of unique
markers for each method in top 0.5% region is also illustrated. A and B: P values are plotted, which are derived
from significance testing from estimates of the attributable proportion due to interaction (AP) in the additive
method and from the interaction term for the multiplicative method (dominant model in black and recessive
model in blue). Threshold for significance after a 1,000-fold permutation analysis accounting for number of
comparisons (5% significance level) are illustrated as well as the cut-off values representing nominal P value and
the top 0.5% of all interactions that were tested in each method. QQ-plots (with 95% C.I.) are illustrated for
additive and multiplicative method. In the QQ-plot of the additive dominant and recessive models negative
estimates of AP values illustrated with green dots. C: Interaction results of ~6.1 million ranked interactions in
the MDR analysis plotted against balanced accuracy value. Threshold after a 1,000-fold permutation analysis is
illustrated as well as the threshold line to define the top 0.5% of all interactions. In a subsequent analysis we
observed that all 63 candidate genes are represented in the top 0.5% region in all tested methods (data not
shown). Moreover, the interactions present among the 0.5% most significant ones were not restricted to a small
group of markers.
Additional file 8: Figure S4. Evaluation of AP values. A: Histogram of AP values. B: The lowest number of
individuals in any exposure group, i.e. A0B0, A0B1, A1B0 or A1B1 (see Methods for definition of exposure groups),
plotted against AP values. C: The lower of the two OR values from single markers (in any of the A0B1 or A1B0
groups) plotted against AP values. D: The higher of the two OR values from single markers (in any of the A0B1 or
A1B0 groups) plotted against AP values.
Additional file 9: Table S4. Detailed results for the 10 most nominally significant interactions. Linear models
are presented in A-D and results from MDR analysis in E. All top 10 interactions of each method are LD filtered
(r2 < 0.2). Abbreviations: AP, attributable proportion due to interaction; Permuted P, permuted P value, corrected
for multiple comparisons; 00, 01, 10 and 11 denotes risk (1) or no risk (0) genotype for marker 1 and marker 2; OR,
odds ratio estimates for the interaction term in the multiplicative method; P values of the multiplicative method
are derived for the interaction term; AUC, area under the curve metrics derived from the ROC analysis (metrics for
the diagnose classifier for a particular set of par-wise markers); For the MDR method OR's are calculated using the
number of cases/controls in high and low risk groups as defined in the MDR analysis; Balanced accuracy, statistical
metrics denotes how accurately individuals are classified into high versus low risk groups; The MDR P values are
derived from test for significance of the OR estimates; TPR (true positive rate) and FPR (false positive rate) is the
sensitivity and specificity metrics to test the diagnose classifier for a particular set of pair-wise markers; PAF,
population attributable fraction, proportion of disease burden in the population due to exposure to genetic risk.
For each MDR risk group (high risk and low risk) are the number of cases/controls and genotype combinations
displayed (-2 denote missing genotype). Notes: Asterisk (*) denotes that recoding of the preventive factors was
made before measures of interaction in the additive scale were calculated. Recoding was done as follows: * 00 to
10, 01 to11, 10 to 00 and 11 to 01. ** 00 to 01, 01 to 11, 10 to 00 and 11 to 10. *** 00 to 11, 01 to 10, 10 to 01 and
11 to 00.
Additional file 10: Figure S5. Overlap of interaction results between different methods. A-L: Comparison of
shared interactions between the top 0.5% regions (red dots) of one particular interaction method with the
complete dataset (black dotted line) of another. The insert figures illustrate the correlation for shared interactions
between two analysis methods. The gray dashed lines depict the highest value of the two methods and the 0.5%
threshold respectively. Pearson’s correlation coefficient (r) was computed for the shared interactions in the top
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0.5% regions. The r statistics and P values for each correlation analysis are depicted. Of note, as shown in the insert
figures there was an absence of observations for shared interactions of the absolute top regions (very few
observations are observed close to the gray dotted lines ‘highest value’). Thus, the remaining shared interactions
yield a marked correlation statistics masking the low correlation of the interactions in the absolute top regions. Of
note, as the interaction analysis in the MDR approach allowed to test all possible pair-wise SNP combinations
which was not practically feasible in the additive or multiplicative models the comparison between the MDR versus
logistic regression models are not fully illustrative.
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